Harrow price target raised to $30 from $26 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Harrow to $30 from $26 and keeps a Buy rating on the shares after Harrow completed a major step toward commercial availability of Triesence. The firm believes the best-case scenario for a Triesence relaunch is sometime in 4Q24, and will thus add Triesence to its 2025 estimates. The firm’s 2024 estimates still have no Triesence contribution, and an early Q4 launch with provide upside.